Scholarlink

Background <p>Accurately predicting progression-free survival (PFS) in patients with advanced lung squamous cell carcinoma (LUSC) receiving immunotherapy remains a clinical challenge. Radiomics has emerged as a promising non-invasive approach; however, its application in this specific patient population remains relatively limited.</p> Methods <p>A total of 129 patients were retrospectively enrolled. Radiomics features were extracted from baseline positron emission tomography/computed tomography (PET/CT) images. Feature reproducibility was evaluated using intraclass correlation coefficients (ICC), and only features with ICC &gt; 0.75, indicating good reproducibility, were retained. A three-step feature selection strategy, including univariate Cox regression, least absolute shrinkage and selection operator (LASSO), and multivariate Cox modeling, was applied to construct the radiomics signature. Model performance was evaluated using time-dependent receiver operating characteristic (ROC) analysis, Kaplan–Meier survival analysis, and bootstrap resampling. Additionally, a 3D convolutional neural network (CNN) model was explored for comparative analysis.</p> Results <p>The final model achieved a 2-year AUC of 0.673. The relatively stable AUC values across time points (1-year: 0.670; 2-year: 0.673; 3-year: 0.651) suggest that the model primarily captures baseline risk stratification rather than strong time-dependent variation. Patients in the high-risk group exhibited a significantly increased risk of progression compared with those in the low-risk group (HR = 4.36, 95% CI: 2.70–7.04, <i>P</i> &lt; 0.001). The radiomics signature remained an independent predictor of PFS in multivariate analysis. In comparison, the 3D CNN model demonstrated inferior predictive performance compared with the radiomics-based model.</p> Conclusion <p>The PET/CT-based radiomics model enables non-invasive risk stratification of patients with advanced LUSC receiving immunotherapy and may provide complementary information for clinical decision-making.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PET/CT Radiomics-based assessment of tumor heterogeneity for predicting immunotherapy outcomes in advanced lung squamous cell carcinoma: a retrospective prognostic modeling study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月22日

查看全文
  • Rui Zhang,
  • Yan Li,
  • Furui Duan,
  • Ximei Wang,
  • Minghui Zhang,
  • Ping Li,
  • Dalong Wang

摘要

Background

Accurately predicting progression-free survival (PFS) in patients with advanced lung squamous cell carcinoma (LUSC) receiving immunotherapy remains a clinical challenge. Radiomics has emerged as a promising non-invasive approach; however, its application in this specific patient population remains relatively limited.

Methods

A total of 129 patients were retrospectively enrolled. Radiomics features were extracted from baseline positron emission tomography/computed tomography (PET/CT) images. Feature reproducibility was evaluated using intraclass correlation coefficients (ICC), and only features with ICC > 0.75, indicating good reproducibility, were retained. A three-step feature selection strategy, including univariate Cox regression, least absolute shrinkage and selection operator (LASSO), and multivariate Cox modeling, was applied to construct the radiomics signature. Model performance was evaluated using time-dependent receiver operating characteristic (ROC) analysis, Kaplan–Meier survival analysis, and bootstrap resampling. Additionally, a 3D convolutional neural network (CNN) model was explored for comparative analysis.

Results

The final model achieved a 2-year AUC of 0.673. The relatively stable AUC values across time points (1-year: 0.670; 2-year: 0.673; 3-year: 0.651) suggest that the model primarily captures baseline risk stratification rather than strong time-dependent variation. Patients in the high-risk group exhibited a significantly increased risk of progression compared with those in the low-risk group (HR = 4.36, 95% CI: 2.70–7.04, P < 0.001). The radiomics signature remained an independent predictor of PFS in multivariate analysis. In comparison, the 3D CNN model demonstrated inferior predictive performance compared with the radiomics-based model.

Conclusion

The PET/CT-based radiomics model enables non-invasive risk stratification of patients with advanced LUSC receiving immunotherapy and may provide complementary information for clinical decision-making.